patients, with bac-teriological cures in 89.7% and 82.4% of patients, respectively.
¹®Çå: US. Pharmacist 2000³â 3¿ùÈ£
Pioglitazone
PioglitazoneÀº 2Çü ´ç´¢º´¿¡ sulfonylu-Rea, metformin, insulinµî°ú °°ÀÌ È¤Àº ´Üµ¶À¸·Î Ç÷´çÀ» Á¶ÀýÇϱâ À§ÇØ ½ÄÀÌ ¹× ¿îµ¿ ¿ä¹ý¿¡ º¸Á¶Á¦·Î ÃßõµÈ´Ù
ºÎÀÛ¿ë: º¸Åë pioglitazoneÀº ÀÓ»ó ¿¬±¸½Ã ¸öÀÌ Àß ¹Þ¾ÆµéÀÌ°í º° ¹®Á¦°¡ ¾ø´Ù. º¸Åë º¸°íµÈ ºÎÀÛ¿ë: µÎÅë, »ó±âµµ °¨¿° ±ÙÀ°Åë, troglitazone¿¡ ºñÇؼ ¾à¹°¶§¹®¿¡ ¾ò¾îÁö´Â °£ µ¶¼ºÀº ÀÓ»ó º¸°í¼¿¡¼´Â Áõ¸íµÇ¾î ÀÖÁö ¾Ê´Ù. ±×·¯³ª FDA°¡ ¨ç Ä¡·á¸¦ ½ÃÀÛÇϱâ Àü¿¡ °£ ±â´ÉÀ» °Ë»çÇÏ°í, ¨è Ä¡·á ù 1³â µ¿¾È 2°³¿ù¸¶´Ù °£ ±â´É °Ë»çÇÏ°í ±â·ÏÇØ¾ß ÇÑ´Ù°í ÃßõÇÑ´Ù
ȯÀÚ¿¡°Ô °£ ±â´É ÀÌ»ó(¿À½É, ±¸Åä, ÇÇ·Î, º¹Åë, ½Ä¿åºÎÁø, ¼Òº¯ »öÀÌ ÁøÇÔ, Ȳ´Þ)ÀÌ ³ª¿À¸é Áï½Ã ÀÇ»ç, ¾à»ç¿¡°Ô À̾߱âÇ϶ó°í °Á¶ÇØ¾ß ÇÑ´Ù (Áï, ÁÖÀǽÃÅ°´Â °ÍÀÌÁö °£¿¡ ÇØ°¡ ²À ÀÖ´Â °ÍÀº ¾Æ´Ï´Ù) ÀϺΠÀ̾àÀ¸·Î Ä¡·á ¹Þ´Â ȯÀÚ¿¡°Ô¼´Â ºÎÁ¾, ÀúÇ÷´ç, ¸¶ºñ, creatinine phosphokinaseÄ¡ »ó½Â µîÀÌ ³ªÅ¸³´Ù. Çì¸ð±Û¸£ºó°ú Ç츶ÅäÅ©¸®Æ® Ä¡ÀÇ °¨¼Òµµ °üÂûµÈ´Ù
glitazone ¿ä¹ýÀº ½ÉºÎÀü 3, 4 ´Ü°è¿¡´Â ÃßõµÇÁö ¾ÊÀ¸¸ç ½ÉºÎÀü 1,2 ´Ü°è¿¡¼´Â ȯÀÚÀÇ Ã¼¾× »óŸ¦ ¸é¹ÐÈ÷ Á¶»çÇØ °¡¸é¼ ¾²´Â °ÍÀÌ ÇÊ¿äÇÏ´Ù. GlitazoneÀ¸·Î Ä¡·á ¹Þ´Â ȯÀڴ üÁßÀÌ
1 – 4 kg ´Ã±âµµ ÇÑ´Ù.
Pioglitazone is officially indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes either as monotherapy or in combination with a sulfonylurea, metformin, or insulin.
Adverse Reactions: In general, pioglitazone was well-tolerated in clinical studies.Adverse events commonly re-ported included headache, upper res-piratory infections, and muscle pain.
In contrast to troglitazone, no evidence of drug-induced hepatotoxicity was noted in clinical studies of pioglitazone.However, the FDA recommends monit-oring hepatic function at the start of pioglitazone therpy and every two mo-nths during the first year of treatment.
Patients should also be advised to mo-nitor for signs and symptoms sugges-tive of hepatic dysfunction such as nausea, vomiting, abdominal pain, fat-igue, anorexia, dark urine, or jaundice.edema, hypoglycemia, paresthesias, and elevations of creatinine phosph-okinase (CPK) have occurred in some pioglitazone-treated patients. Reductions in hemoglobin and hematocrit have also been observed.
Glitazone therapy is not recommended for class ¥² and ¥³ CHF patients and close monitoring of the fluid status< ÀúÀÛ±ÇÀÚ © ¾à±¹½Å¹® ¹«´ÜÀüÀç ¹× Àç¹èÆ÷±ÝÁö > |
|
|
|
|
ÀÌ ±â»ç¿¡ ´ëÇÑ ´ñ±Û À̾߱â (0) |
|
|
|